Why do some lung cancer patients relapse early on targeted therapy? Our study with Drs. K Prabhash, @VanitaNoronha & team from @TataMemorial in collab with Drs. J Khandare, G Shafi, & team from @onecelldx published in ESMO Open (@ESMO_Open) sheds insights. https://t.co/satjKr2eX8
The Tail & Tango of Cancer genome-- we developed a tool โDOMEโ to tame the tail of rare mutations; in another study, we describe the first chromosomal tango โChr 11/5 fusionโ in oral cancer genome. Thanks to @ACTREC_TMC,@CRI_ACTREC,@DBTIndia,@India_Alliance,@DAEIndia,@UnivofDelhi
Delighted to share the findings from my PhD thesis, highlighting the role of a novel oncogenic fusion transcript, UBE3C-LRP5, in oral cancer. Pyrvinium pamoate targets the fusion-positive tumors! Highly grateful to @amtdutt for the support and encouragement. Kudos to the team!!
UBE3C-LRP5, novel oncogenic fusion-transcript in oral cancer @ 5.3% in Indian & 1.2% TCGA patients. Kudos to @dbhaskarjnv & Ashwin Butle in collab with Dr. Sudhir Nair! Pyrv' pamoate, an FDA approved dewormer, targets this fusion. A potential game-changer! https://t.co/gqj8MH6T05
@Neelima__Yadav@amtdutt Thank you so much @Neelima__Yadav for your kind words and wishes! I am highly grateful to you for all the help, support and encouragement throughout my PhD journey!! Wish you good luck for all your future endeavours!
@desaisanket12@amtdutt@CRI_ACTREC Thank you for the immense help in the analysis and for the intellectual inputs and discussions. Always a pleasure working with you. Hope our paths cross again in future.